PROTOCOL NIDA-CTN-0027-A-1


START Pharmacogenetics: Exploratory Genetic Studies in Starting Treatment with Agonist Replacement Therapies

Wade Berretini, MD, PhD
Co-Lead Investigator
Professor, Department of Psychiatry
Translational Research Laboratory Building
wadeb@mail.med.upenn.edu

C. Lindsay DeVane, PharmD
Co-Lead Investigator
Professor and Vice Chair for Research
Clinical Neuroscience Division, Department of Psychiatry and Behavioral Sciences
Medical University of South Carolina
devanel@musc.edu

This ancillary study is related to CTN-0027, "Starting Treatment with Agonist Replacement Therapies (START)."

Patients participating in START will be offered the opportunity to volunteer for a genetics study that has the primary objective of genotyping patients for exploratory analyses.  Genomic DNA from blood samples sent to the NIDA Genetics Repository will be extracted and saved for future study.  Investigators at the University of Pennsylvania will study the frequency of gene variants that have primarily been associated with addiction, while the Medical University of South Carolina researchers will examine the relationship between treatment drug plasma concentrations and gene variants associated with drug disposition and transport.

RELATED STUDIES
RELATED RESOURCES

snowflake

Publications about CTN-0027-A-1


 

Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 2/2011 -- http://ctndisseminationlibrary.org/protocols/ctn0027a1.htm
info@ctndisseminationlibrary.org